Literature DB >> 21302294

Involvement of L-type calcium channel and SERCA2a in myocardial dysfunction induced by obesity.

André Soares Leopoldo1, Ana Paula Lima-Leopoldo, Mário Mateus Sugizaki, André Ferreira do Nascimento, Dijon Henrique Salomé de Campos, Renata de Azevedo Melo Luvizotto, Edson Castardeli, Carlos Augusto Barnabé Alves, Patrícia Chakur Brum, Antonio Carlos Cicogna.   

Abstract

Obesity has been shown to impair myocardial performance. Nevertheless, the mechanisms underlying the participation of calcium (Ca(2+) ) handling on cardiac dysfunction in obesity models remain unknown. L-type Ca(2+) channels and sarcoplasmic reticulum (SR) Ca(2+) -ATPase (SERCA2a), may contribute to the cardiac dysfunction induced by obesity. The purpose of this study was to investigate whether myocardial dysfunction in obese rats is related to decreased activity and/or expression of L-type Ca(2+) channels and SERCA2a. Male 30-day-old Wistar rats were fed standard (C) and alternately four palatable high-fat diets (Ob) for 15 weeks. Obesity was determined by adiposity index and comorbidities were evaluated. Myocardial function was evaluated in isolated left ventricle papillary muscles under basal conditions and after inotropic and lusitropic maneuvers. L-type Ca(2+) channels and SERCA2a activity were determined using specific blockers, while changes in the amount of channels were evaluated by Western blot analysis. Phospholamban (PLB) protein expression and the SERCA2a/PLB ratio were also determined. Compared with C rats, the Ob rats had increased body fat, adiposity index and several comorbidities. The Ob muscles developed similar baseline data, but myocardial responsiveness to post-rest contraction stimulus and increased extracellular Ca(2+) was compromised. The diltiazem promoted higher inhibition on developed tension in obese rats. In addition, there were no changes in the L-type Ca(2+) channel protein content and SERCA2a behavior (activity and expression). In conclusion, the myocardial dysfunction caused by obesity is related to L-type Ca(2+) channel activity impairment without significant changes in SERCA2a expression and function as well as L-type Ca(2+) protein levels.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21302294     DOI: 10.1002/jcp.22643

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  22 in total

Review 1.  Mechanisms of cardiac dysfunction in obstructive sleep apnea.

Authors:  Jean-Philippe Baguet; Gilles Barone-Rochette; Renaud Tamisier; Patrick Levy; Jean-Louis Pépin
Journal:  Nat Rev Cardiol       Date:  2012-09-25       Impact factor: 32.419

2.  Long-term obesity promotes alterations in diastolic function induced by reduction of phospholamban phosphorylation at serine-16 without affecting calcium handling.

Authors:  Ana Paula Lima-Leopoldo; André S Leopoldo; Danielle C T da Silva; André F do Nascimento; Dijon H S de Campos; Renata A M Luvizotto; Adriana F de Deus; Paula P Freire; Alessandra Medeiros; Katashi Okoshi; Antonio C Cicogna
Journal:  J Appl Physiol (1985)       Date:  2014-06-26

Review 3.  Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Jun Ren; Ne N Wu; Shuyi Wang; James R Sowers; Yingmei Zhang
Journal:  Physiol Rev       Date:  2021-05-05       Impact factor: 37.312

4.  Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process.

Authors:  Liliana Perdomo; Nuria Beneit; Yolanda F Otero; Óscar Escribano; Sabela Díaz-Castroverde; Almudena Gómez-Hernández; Manuel Benito
Journal:  Cardiovasc Diabetol       Date:  2015-06-10       Impact factor: 9.951

5.  Cardiac Dysfunction Induced by Obesity Is Not Related to β-Adrenergic System Impairment at the Receptor-Signalling Pathway.

Authors:  Artur Junio Togneri Ferron; Bruno Barcellos Jacobsen; Paula Grippa Sant'Ana; Dijon Henrique Salomé de Campos; Loreta Casquel de Tomasi; Renata de Azevedo Mello Luvizotto; Antonio Carlos Cicogna; André Soares Leopoldo; Ana Paula Lima-Leopoldo
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

6.  Obesity preserves myocardial function during blockade of the glycolytic pathway.

Authors:  Dijon Henrique Salomé de Campos; André Soares Leopoldo; Ana Paula Lima-Leopoldo; André Ferreira do Nascimento; Silvio Assis de Oliveira-Junior; Danielle Cristina Tomaz da Silva; Mario Mateus Sugizaki; Carlos Roberto Padovani; Antonio Carlos Cicogna
Journal:  Arq Bras Cardiol       Date:  2014-09-12       Impact factor: 2.000

7.  Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis.

Authors:  Jingxue Ye; Ruiying Wang; Min Wang; Jianhua Fu; Qiong Zhang; Guibo Sun; Xiaobo Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-21       Impact factor: 6.543

8.  Extensive impact of saturated fatty acids on metabolic and cardiovascular profile in rats with diet-induced obesity: a canonical analysis.

Authors:  Silvio A Oliveira Junior; Carlos R Padovani; Sergio A Rodrigues; Nilza R Silva; Paula F Martinez; Dijon Hs Campos; Marina P Okoshi; Katashi Okoshi; Maeli Dal-Pai; Antonio C Cicogna
Journal:  Cardiovasc Diabetol       Date:  2013-04-15       Impact factor: 9.951

9.  Obesity Resistance Promotes Mild Contractile Dysfunction Associated with Intracellular Ca2+ Handling.

Authors:  Felipe Gonçalves Dos Santos de Sá; Ana Paula Lima-Leopoldo; Bruno Barcellos Jacobsen; Artur Junio Togneri Ferron; Wagner Muller Estevam; Dijon Henrique Salomé Campos; Edson Castardeli; Márcia Regina Holanda da Cunha; Antonio Carlos Cicogna; André Soares Leopoldo
Journal:  Arq Bras Cardiol       Date:  2015-10-27       Impact factor: 2.000

10.  AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity.

Authors:  Silvio A Oliveira-Junior; Paula F Martinez; Danielle M Guizoni; Dijon H S Campos; Tiago Fernandes; Edilamar M Oliveira; Marina P Okoshi; Katashi Okoshi; Carlos R Padovani; Antonio C Cicogna
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.